SMMT
Summit Therapeutics Inc.
$14.01
+7.11%
$10.9B
No data for this timeframe.
Vol
Market Cap$10.9B
Cap SizeLarge Cap
Analyst ConsensusBuy (67%)
Inst. Holders50 funds
Inst. Value$1.8B
Inst. Activity12 buys / 6 sells
Insider Activity5B / 0S
Insider Net $$103.3M
Reddit Sentiment38° Cool
SEC Reports10
Recent Activity
Nov 14, 2026
fda_pdufa
PDUFA: SMMT — ivonescimab in EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) post-TKI therapy — 2026-11-14
FDA target action date 2026-11-14 for SMMT (Summit Therapeutics Inc.). Drug: ivonescimab. Indication
Jun 12, 2026
SEC
Both co-CEOs of Summit Therapeutics (SMMT) each purchased 3.81M shares open-market on June 12, 2026, at $13.12, aggregat
CLUSTER — Impact 6/10
Jun 12, 2026
SEC
The Q3 2024 institutional cluster for Summit Therapeutics (SMMT) shows net buying of $64.7M across 12 buyers and net sel
INST-CLUSTER — Impact 4/10
Jun 12, 2026
Insider
DUGGAN ROBERT W bought 3,810,000 shares
Co-Chief Executive Officer @ $13.12 ($50.0M)
Jun 12, 2026
Insider
Zanganeh Mahkam bought 3,810,000 shares
Co-Chief Executive Officer @ $13.12 ($50.0M)
Jun 11, 2026
SEC
Three mega-passive institutional investors (Vanguard, State Street, Morgan Stanley) collectively added $122.6M to their
INST-CLUSTER — Impact 3/10
Jun 4, 2026
Insider
DUGGAN ROBERT W bought 100,000 shares
Co-Chief Executive Officer @ $14.60 ($1.5M)
Inst.
MORGAN STANLEY — ADD
1,650,591 shares ($31.3M)
Price Targets
$28.52
+103.6% upside
Strong Buy
Current $14.01
Low $7.71
Median $32.76
High $44.77
13 analysts
$7.71
$44.77
Analyst Ratings
5Strong Buy
11Buy
6Hold
1Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 22, 2026 | Bernstein | INITIATE | Underperform |
| May 22, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 1, 2026 | Piper Sandler | MAINTAIN | Neutral → Neutral |
| Apr 8, 2026 | Stifel | INITIATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.21 ▲ +3.7% | $-0.34 — $-0.13 | 62% YoY | 11 |
| Next Q | $-0.22 ▲ +2.9% | $-0.29 — $-0.13 | 5% YoY | 10 |
| Current FY | $-0.82 ▼ -4.6% | $-1.18 — $-0.56 | 23% YoY | 11 |
| Next FY | $-0.88 ▼ -4.0% | $-1.22 — $-0.61 | -7% YoY | 10 |
Latest Reports
BULLISH
CLUSTER
6/10
Both co-CEOs of Summit Therapeutics (SMMT) each purchased 3.81M shares open-market on June 12, 2026, at $13.12, aggregat
Jun 12, 2026
MIXED
INST-CLUSTER
4/10
The Q3 2024 institutional cluster for Summit Therapeutics (SMMT) shows net buying of $64.7M across 12 buyers and net sel
Jun 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| BAKER BROS. ADVISORS LP | $690.0M | — |
| FMR LLC | $205.8M | ADD |
| BlackRock, Inc. | $183.0M | ADD |
| STATE STREET CORP | $133.3M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 12, 2026 | DUGGAN ROBERT | BUY | $50.0M |
| Jun 12, 2026 | Zanganeh Mahkam | BUY | $50.0M |
| Jun 4, 2026 | DUGGAN ROBERT | BUY | $1.5M |
| Jun 4, 2026 | Zanganeh Mahkam | BUY | $1.5M |
| Jun 4, 2026 | Soni Manmeet | BUY | $361.5K |
Reddit Sentiment
38°
Cool
Bearish
Neutral
Bullish
50 institutional holders with $1.8B total value (95,806,063 shares) as of 2026-Q1. Top holders: NOMURA, BAKER, FMR. Net buying activity: 12 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | BAKER BROS. ADVISORS LP | 36,391,063 | $690.0M | 38.0% | — |
| 3 | FMR LLC | 10,853,199 | $205.8M | 11.3% | ADD +49.8% |
| 4 | BlackRock, Inc. | 9,653,758 | $183.0M | 10.1% | ADD +27.1% |
| 5 | STATE STREET CORP | 7,028,160 | $133.3M | 7.3% | ADD +58.3% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 5,711,802 | $108.3M | 6.0% | — |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5,233,252 | $99.2M | 5.5% | — |
| 8 | D. E. Shaw & Co., Inc. | 2,242,229 | $42.5M | 2.3% | DOUBLED +217.9% |
| 9 | MORGAN STANLEY | 1,650,591 | $31.3M | 1.7% | ADD +78.1% |
| 10 | Pictet Asset Management Holding SA | 1,323,179 | $24.0M | 1.3% | TRIM -25.9% |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,239,300 | $23.5M | 1.3% | — |
| 12 | TWO SIGMA INVESTMENTS, LP | 981,185 | $18.6M | 1.0% | DOUBLED +2210.2% |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 960,867 | $18.2M | 1.0% | — |
| 14 | TD ASSET MANAGEMENT INC | 956,894 | $18.1M | 1.0% | DOUBLED +124.2% |
| 15 | VANGUARD FIDUCIARY TRUST CO | 934,394 | $17.7M | 1.0% | — |
| 16 | Point72 Asset Management, L.P. | 784,186 | $14.9M | 0.8% | NEW |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 603,933 | $11.5M | 0.6% | — |
| 18 | LMR Partners LLP | 600,400 | $11.4M | 0.6% | TRIM -54.6% |
| 19 | BANK OF AMERICA CORP /DE/ | 598,692 | $11.4M | 0.6% | ADD +25.4% |
| 20 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 592,810 | $11.2M | 0.6% | ADD +34.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 926,579 | 1,650,591 | +78.1% | $31.3M | 2026-Q1 |
| Point72 Asset Management, L.P. | NEW | — | 784,186 | — | $14.9M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 477,393 | 598,692 | +25.4% | $11.4M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 440,953 | 592,810 | +34.4% | $11.2M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 50,298 | 548,335 | +990.2% | $10.4M | 2026-Q1 |
| NOMURA HOLDINGS INC | TRIM | 542,234 | 313,981 | -42.1% | $6.0M | 2026-Q1 |
| Beacon Pointe Advisors, LLC | DOUBLED | 39,611 | 94,394 | +138.3% | $1.8M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | NEAR_EXIT | 376,563 | 88,496 | -76.5% | $1.7M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | TRIM | 92,882 | 62,535 | -32.7% | $1.2M | 2026-Q1 |
| GROUP ONE TRADING LLC | ADD | 31,410 | 42,781 | +36.2% | $811.1K | 2026-Q1 |
| Verition Fund Management LLC | NEAR_EXIT | 228,990 | 36,163 | -84.2% | $685.6K | 2026-Q1 |
| LMR Partners LLP | TRIM | 75,200 | 34,122 | -54.6% | $647.0K | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 10,063 | 19,681 | +95.6% | $373.2K | 2026-Q1 |
| NATIONAL BANK OF CANADA /FI/ | ADD | 1,695 | 2,223 | +31.2% | $42.2K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 489 | 1,243 | +154.2% | $23.6K | 2026-Q1 |
| CWM, LLC | DOUBLED | 295 | 1,131 | +283.4% | $21.4K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 69 | 270 | +291.3% | $5.1K | 2026-Q1 |
| NORGES BANK | EXIT | 1,373,943 | 0 | -100.0% | $0.00 | 2026-Q1 |
| FMR LLC | ADD | 8,917,887 | 13,360,807 | +49.8% | $233.7M | 2025-Q4 |
| BlackRock, Inc. | ADD | 7,363,793 | 9,361,921 | +27.1% | $163.7M | 2025-Q4 |
| NORGES BANK | NEW | — | 1,373,943 | — | $24.0M | 2025-Q4 |
| TD ASSET MANAGEMENT INC | DOUBLED | 537,530 | 1,205,272 | +124.2% | $21.1M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 1,926,828 | 926,579 | -51.9% | $16.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 25,030 | 578,248 | +2210.2% | $10.1M | 2025-Q4 |
| NOMURA HOLDINGS INC | TRIM | 1,048,927 | 542,234 | -48.3% | $9.5M | 2025-Q4 |
3 unique insiders with 5 transactions. Net insider value: $103.3M ($103.3M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | DUGGAN ROBERT W | Co-Chief Executive Officer | BUY | 3,810,000 | $13.12 | $50.0M |
| Jun 12, 2026 | Zanganeh Mahkam | Co-Chief Executive Officer | BUY | 3,810,000 | $13.12 | $50.0M |
| Jun 4, 2026 | DUGGAN ROBERT W | Co-Chief Executive Officer | BUY | 100,000 | $14.60 | $1.5M |
| Jun 4, 2026 | Zanganeh Mahkam | Co-Chief Executive Officer | BUY | 100,000 | $14.60 | $1.5M |
| Jun 4, 2026 | Soni Manmeet Singh | COO and CFO | BUY | 25,000 | $14.46 | $361.5K |
10 SEC filing reports analyzed. Sentiment: 4 bullish, 1 bearish, 1 mixed, 4 neutral. Avg impact: 4.8/10.
BULLISH
CLUSTER
6/10
Both co-CEOs of Summit Therapeutics (SMMT) each purchased 3.81M shares open-market on June 12, 2026,
Jun 12, 2026
MIXED
INST-CLUSTER
4/10
The Q3 2024 institutional cluster for Summit Therapeutics (SMMT) shows net buying of $64.7M across 1
Jun 12, 2026
NEUTRAL
INST-CLUSTER
3/10
Three mega-passive institutional investors (Vanguard, State Street, Morgan Stanley) collectively add
Jun 11, 2026
BEARISH
S-3ASR
7/10
Summit Therapeutics filed an S-3ASR shelf registration on June 9, 2026, with no specified offering s
Jun 9, 2026
BULLISH
CLUSTER
5/10
Both co-CEOs and the COO/CFO of Summit Therapeutics made open-market purchases totaling $3.28M on Ju
Jun 4, 2026
BULLISH
CLUSTER
6/10
Co-CEO Mahkam Zanganeh and COO/CFO Manmeet Singh collectively purchased $1.82M in open-market shares
Jun 4, 2026
NEUTRAL
8-K
3/10
Summit Therapeutics disclosed that its Audit Committee and independent directors approved company af
Jun 3, 2026
BULLISH
8-K
7/10
Summit Therapeutics announced positive Phase III HARMONi-6 overall survival results for ivonescimab
Jun 1, 2026
NEUTRAL
8-K
5/10
Summit Therapeutics reported Q1 2026 financial results and operational progress. The company posted
Apr 30, 2026
NEUTRAL
DEFA14A
2/10
Summit Therapeutics Inc. has filed a definitive proxy statement (DEFA14A) for its upcoming annual sh
Apr 17, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (67% buy). Based on 24 analysts: 5 strong buy, 11 buy, 6 hold, 1 sell, 1 strong sell.
Analyst Price Targets
$28.52 mean target
+103.6% upside
Strong Buy (2.00)
$7.71 Low
$44.77 High
| Metric | Value |
|---|---|
| Current Price | $14.01 |
| Target Low | $7.71 |
| Target Mean | $28.52 |
| Target Median | $32.76 |
| Target High | $44.77 |
| # Analysts | 13 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.21 | $-0.34 | $-0.13 | 62.2% | +3.7% | 2↑ 2↓ | $0.0B | 0.0% | 11 |
| Next Q 2026-09-30 |
$-0.22 | $-0.29 | $-0.13 | 5.5% | +2.9% | 2↑ 1↓ | $0.0B | 0.0% | 10 |
| Current FY 2026-12-31 |
$-0.82 | $-1.18 | $-0.56 | 22.7% | -4.6% | 0↑ 3↓ | $0.0B | 0.0% | 11 |
| Next FY 2027-12-31 |
$-0.88 | $-1.22 | $-0.61 | -6.9% | -4.0% | 1↑ 3↓ | $0.0B | 1615.5% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.214 | |
| 7d ago | $-0.214 | -0.001 |
| 30d ago | $-0.222 | +0.008 |
| 60d ago | $-0.225 | +0.011 |
| 90d ago | $-0.234 | +0.020 |
7 analyst firms have rated this stock: 1 upgrades, 2 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 22, 2026 | Bernstein | INITIATE | — | Underperform |
| May 22, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 1, 2026 | Piper Sandler | MAINTAIN | Neutral | Neutral |
| Apr 8, 2026 | Stifel | INITIATE | Buy | Buy |
| Mar 16, 2026 | Jefferies | DOWNGRADE | Buy | Hold |
| Feb 24, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 30, 2026 | Citizens | REITERATE | Market Outperform | Market Outperform |
| Dec 17, 2025 | Barclays | UPGRADE | Underweight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 11 | 6 | 1 | 1 | 67% | |
| May 1, 2026 | 5 | 13 | 5 | 1 | 0 | 75% | |
| Apr 1, 2026 | 4 | 13 | 5 | 1 | 0 | 74% | |
| Mar 1, 2026 | 5 | 13 | 4 | 1 | 0 | 78% | |
| Feb 1, 2026 | 5 | 13 | 4 | 1 | 0 | 78% | |
| Jan 1, 2026 | 5 | 13 | 4 | 1 | 0 | 78% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
38°
Cool
Bearish
Neutral
Bullish
4 mentions
0 bullish
2 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Jun 1, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 5, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 5, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Very confused by $SMMT
▲ 1
💬 0
⚡ 0.2
Nov 14, 2026
fda_pdufa
PDUFA: SMMT — ivonescimab in EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) post-TKI therapy — 2026-11-14
FDA target action date 2026-11-14 for SMMT (Summit Therapeutics Inc.). Drug: ivonescimab. Indication: EGFR-mutated locally advanced or metastatic non-
Jun 10, 2026
short_volume
Short Volume: SMMT — 66.0% short (2.2M / 3.3M)
Short: 2,203,992 | Exempt: 80,369 | TRF Vol: 3,341,408 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: SMMT — 58.6% short (1.2M / 2.1M)
Short: 1,239,459 | Exempt: 2,415 | TRF Vol: 2,116,227 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: SMMT — 61.6% short (1.4M / 2.3M)
Short: 1,398,305 | Exempt: 2,682 | TRF Vol: 2,270,719 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: SMMT — 56.6% short (1.4M / 2.5M)
Short: 1,397,927 | Exempt: 587 | TRF Vol: 2,470,246 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: SMMT — 59.3% short (2.8M / 4.7M)
Short: 2,777,939 | Exempt: 175,164 | TRF Vol: 4,684,492 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: SMMT — 70.7% short (2.0M / 2.8M)
Short: 1,958,528 | Exempt: 4,527 | TRF Vol: 2,771,896 | Short Ratio: 70.7% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: SMMT — 63.3% short (1.2M / 1.9M)
Short: 1,231,390 | Exempt: 27,921 | TRF Vol: 1,944,386 | Short Ratio: 63.3% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: SMMT — 68.6% short (0.5M / 0.7M)
Short: 474,650 | Exempt: 0 | TRF Vol: 691,984 | Short Ratio: 68.6% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: SMMT — 60.3% short (1.0M / 1.7M)
Short: 1,045,864 | Exempt: 62,612 | TRF Vol: 1,732,999 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: SMMT — 69.5% short (1.8M / 2.5M)
Short: 1,765,237 | Exempt: 83,248 | TRF Vol: 2,538,596 | Short Ratio: 69.5% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: SMMT — 63.9% short (0.6M / 0.9M)
Short: 580,598 | Exempt: 432 | TRF Vol: 908,345 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: SMMT — 69.8% short (0.6M / 0.9M)
Short: 636,980 | Exempt: 0 | TRF Vol: 912,446 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: SMMT — 66.3% short (1.2M / 1.8M)
Short: 1,169,466 | Exempt: 159,524 | TRF Vol: 1,765,038 | Short Ratio: 66.3% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: SMMT — 5.0M shares, 74,213 trades
Week starting 2026-05-18. Total ATS volume: 5,047,285 shares across 74,213 trades.